Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

NCT01652872 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01652872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01652872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
July 30, 2012
Completion date
October 19, 2017
Enrollment
756 (actual)
Sites
249

Conditions

As the registry lists them; a condition with its own page is linked.

anemia in chronic kidney disease patients not on dialysis